Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1913535 | 0.83 | MEN1 (0.56) | MEN1KMT2ATDP1DPP7SIGMAR1 | |
| SCHEMBL9316674 | 0.82 | MEN1 (0.47) | MEN1KMT2ATDP1DPP7MAOA | |
| SCHEMBL19882179 | 0.80 | CA12 (0.49) | TDP1DPP7CYP3A4CA12CA1 | |
| SCHEMBL10740603 | 0.80 | SMN1; SMN2 (0.60) | MEN1KMT2ATDP1MAPTGAA | |
| SCHEMBL12809838 | 0.79 | MEN1 (0.52) | MEN1KMT2ATDP1DPP7MAOA | |
| SCHEMBL19273403 | 0.79 | MEN1 (0.52) | MEN1KMT2ATDP1DPP7SIGMAR1 | |
| SCHEMBL16935682 | 0.79 | MEN1 (0.52) | MEN1KMT2ATDP1DPP7MAOA | |
| SCHEMBL29204655 | 0.79 | SIGMAR1 (0.64) | MEN1KMT2ASIGMAR1 | |
| SCHEMBL15826100 | 0.79 | DPP7 (0.58) | MEN1KMT2ADPP7CHRM2GAA | |
| SCHEMBL24712403 | 0.78 | ALDH1A1 (0.43) | MEN1KMT2ATDP1DPP7MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108822037-B | Method for efficiently synthesizing imidazoline derivative with high atom economy | 复旦大学 | 2021-08-20 | — | — | CN | claimed |
| CN-117447334-A | Method for efficiently synthesizing alpha-amino acetal | 南京工业大学 | 2024-01-26 | — | — | CN | disclosed |
| CN-108822037-B | Method for efficiently synthesizing imidazoline derivative with high atom economy | 复旦大学 | 2021-08-20 | — | — | CN | disclosed |
| EP-2686325-B1 | MORPHOLINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2016-12-14 | — | — | EP | disclosed |
| US-9181273-B2 | Morpholine-spirocyclic piperidine amides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150025073-A1 | MORPHOLINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2015-01-22 | — | — | US | disclosed |
| US-8828996-B2 | Morpholine-spirocyclic piperidine amides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-09 | — | — | US | disclosed |
| US-8729274-B2 | Tricyclic heterocyclic derivatives | MERCK SHARP & DOHME B.V. (NL) | 2014-05-20 | — | — | US | disclosed |
| US-8729274-B2 | Tricyclic heterocyclic derivatives | MERCK SHARP & DOHME B.V. (NL) | 2014-05-20 | — | — | US | disclosed |
| US-8729274-B2 | Tricyclic heterocyclic derivatives | MERCK SHARP & DOHME B.V. (NL) | 2014-05-20 | — | — | US | disclosed |
| EP-1828207-B1 | THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2009-10-28 | — | — | EP | disclosed |
| EP-1828207-B1 | THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2009-10-28 | — | — | EP | disclosed |
| US-20090233919-A1 | THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2009-09-17 | — | — | US | disclosed |
| US-20090233919-A1 | THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2009-09-17 | — | — | US | disclosed |
| US-20090233919-A1 | THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2009-09-17 | — | — | US | disclosed |
| EP-1828207-A1 | THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006066174-A1 | THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2006-06-22 | — | — | WO | disclosed |
| EP-0009302-B1 | CLAVULANIC ACID DERIVATIVES AND PROCESS FOR THEIR PREPARATION | BEECHAM GROUP PLC (GB) | 1983-10-26 | — | — | EP | disclosed |
| US-4359473-A | α-Amino deoxy clavulanic acid antibacterial agents | BEECHAM GROUP LIMITED (GB) | 1982-11-16 | — | — | US | disclosed |
| EP-0009302-A1 | Clavulanic acid derivatives and process for their preparation | BEECHAM GROUP PLC (GB) | 1980-04-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025073-A1 | MORPHOLINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | KCNJ2, TRPM5, KCNQ1 | MEN1 1878/4885KMT2A 1876/4885TDP1 4146/4885 |
| US-20090233919-A1 | THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS | MCHR1, MCHR2, MC1R | MEN1 660/4885KMT2A 588/4885TDP1 2242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.